Shanghai, August 27, 2026 – The 2nd International Aesthetic Medicine Leadership Summit, hosted by Singclean Medical, was held at W Shanghai – The Bund, within the IMCAS China Congress venue. Under the theme “Global Vision, Opening a New Chapter,” the summit served as a cross‑border, multi‑disciplinary platform for professional exchange, gathering an impressive lineup of leading physicians and global partners.

Three distinguished speakers delivered keynote presentations: Dr. Zhu Yuan, a renowned Chinese expert in osteological aesthetics; Dr. Diogo Melo, a celebrated Brazilian plastic surgeon; and Mr. Antoine Clavier‑Choo, Chief Commercial Officer and Head of Asia‑Pacific at HTL Biotechnology. Their sessions centered on Singclean Medical’s two flagship products – Singfiller and Singderm – covering injection techniques, aesthetic protocols, raw material quality control, and international clinical applications. The discussions charted new pathways for standardised, high‑quality development in the medical aesthetics industry.

Holistic Aesthetic Strategies for Three High‑Value Zones
Dr. Zhu Yuan, Chief Expert in Skeletal Aesthetics at Huamei Group, presented “Precision Injection Strategies for Holistic Hyaluronic Acid Aesthetics.” She focused on three high‑demand contouring projects – shoulder reshaping, tear‑trough augmentation, and lip volumisation – noting that these high‑mobility areas demand exceptional support, stability, and tissue integration from filler materials.

She introduced an innovative combined approach: botulinum toxin to soften the trapezius muscle plus hyaluronic acid reinforcement of the acromion bone points, achieving both structural definition and natural dynamics. Through clinical case studies, she detailed the aesthetic rationale and precise injection techniques for tear‑trough and lip enhancements. Drawing on her extensive experience, Dr. Zhu highly praised the Singfiller line: “In my practice, I often combine Singfiller 1.0 (firm version) and Singfiller 0.75×2 (dynamic version) for full‑face treatments. The products provide solid contouring and natural resilience, perfectly suited for dynamic aesthetics. They also exhibit excellent compatibility with collagen and regenerative materials, delivering synergistic effects beyond expectations.”

Four‑Dimensional Assessment for Personalised Treatment Plans
Dr. Diogo Melo, founder of the Diogo Melo Training Institute in Brazil, delivered a compelling talk titled “Individualised Full‑Face Hyaluronic Acid Treatment Plans Based on Facial Morphotype Classification.” He advocated a systematic diagnostic approach that moves beyond one‑size‑fits‑all protocols, emphasising a four‑dimensional assessment – age, facial shape, bone structure, and treatment cycle.

He outlined a strict treatment sequence: first, botulinum toxin adjustment; second, skeletal evaluation; third, projection reconstruction and fat volume restoration; and finally, fine contour refinement. This stepwise logic avoids the common pitfall of filling wrinkles prematurely without addressing underlying structural issues. He also recommended phased treatment over short, medium, and long cycles for progressive, natural results. Dr. Melo noted, “Singfiller and Singderm offer outstanding support and stable resistance to deformation, making them ideal for every stage – from skeletal reconstruction to volume restoration to micro‑refinements – ultimately enabling long‑lasting, natural, and personalised outcomes.”

Premium Raw Materials as the Cornerstone of Quality
Mr. Antoine Clavier‑Choo, Chief Commercial Officer and Head of Asia‑Pacific at HTL Biotechnology, shared insights in his presentation “HTL Biotechnology – A Trusted Global Partner in Regenerative Medicine.” He provided a deep dive into the raw material supply chain that underpins the Singfiller brand. HTL Biotechnology has specialised in biopolymers for 45 years, with seven global offices and business reach in over 30 countries. Its hyaluronic acid raw materials are sourced from French production facilities, adhering to strict European regulations. Using proprietary patented bacterial fermentation and multi‑stage purification technologies, HTL produces high‑purity hyaluronic acid fibres with impurity levels far below pharmacopoeia standards. The materials have passed GMP compliance inspections from French ANSM, U.S. FDA, Korean MFDS, and Japanese PMDA, ensuring maximum safety. The unique fibrous, fluffy structure also enhances tissue adaptability and integration, resulting in a softer, more natural post‑injection feel.

In 2022, Singclean Medical entered a strategic partnership with HTL Biotechnology, upgrading the entire Singfiller product line with top‑tier global supply chain support – a move that cemented quality assurance from the raw material stage.

A Milestone in Global Strategy and Academic Collaboration
The successful conclusion of this summit marks a significant milestone in Singclean Medical’s globalisation strategy and its commitment to academic co‑development. Looking ahead, the company will continue to deepen strategic supply chain collaborations, reinforce raw material and product quality, and pursue parallel innovation in technology and clinical research. Singclean Medical remains dedicated to building an open, cross‑border academic platform that empowers physician skill advancement. At the same time, the brand will uphold the highest standards of safety, compliance, and natural refinement, providing consumers with superior, precision‑tailored aesthetic experiences. Through these efforts, Singclean Medical aims to drive sustainable innovation in the medical aesthetics industry and co‑create a new chapter in global aesthetics.